



P R E S S R E L E A S E

Lelystad, the Netherlands, 23 April 2010

AGM APPROVES PAYMENT OF SPECIAL DIVIDEND FORNIX BIOSCIENCES

Biopharmaceutical company Fornix BioSciences N.V. (Euronext Amsterdam: AFORBI) announces that, at the General Meeting of Shareholders (AGM) held in Lelystad, the Netherlands, the company's shareholders today approved Fornix BioSciences' proposal to pay a special dividend of €2.22 per share from the company's freely distributable reserves. The special dividend will be paid entirely in cash subject to deduction of 15% dividend tax.

The AGM furthermore approved the proposal to pay out the full net profit for the financial year 2009 as dividend. On a per share basis this amounts to a dividend of €1.43 per share. After deduction of the interim dividend (with stock option) of €0.65 per share paid in September 2009, a final cash dividend remains of €0.78 per share, subject to deduction of 15% dividend tax.

The Fornix BioSciences share will be listed ex-dividend on 27 April 2010. Payment of both the final dividend and the special dividend will take place on 20 May 2010.

END OF PRESS RELEASE

For more information, please contact: Fornix BioSciences N.V.

C.L. Bergman, CEO

Tel. (0320) 26 77 99

Website: www.fornix.nl

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam: AFORBI) which engages mainly in the development and sale of diagnostic and therapeutic allergen products and the distribution of medical aids and medical and nursing consumables.

Fornix BioSciences N.V. has sites in Lelystad, Beuningen and Hamburg. The company currently has 138 employees and operates mainly in the Netherlands and Germany. Its activities are conducted by two divisions, the Allergy Division consisting of Artu Biologicals Europe and the Medical Aids Division. The activities of Artu Biologicals Deutschland are conducted separately from these two divisions.

The Allergy Division focuses on the development, production and sale of a wide range of patient-friendly immunotherapeutic products including the Oralgen[®] and Igevac[®] brands. These products are administered in the causal treatment of allergies triggered by various allergens, such as grass and tree pollen and house-dust mites. The development programme is supported by high-quality R&D activities and pan-European clinical studies on the effectiveness and safety of the various products. Clinical research should over time lead to the registration of the company's most important allergen products Oralgen[®] Grass Pollen, Tree Pollen and House-dust mite. In the coming years, the company intends to increase its focus on allergen products and to expand its position in the growing immunotherapy market in Europe.

Artu Biologicals Deutschland in Hamburg carries a growing range of medical aids in Germany on an exclusive basis. The Oralgel[®] equivalent Igevac[®] is also distributed in this market on a named-patient basis.

The Medical Aids Division consists of Laprolan, located in Beuningen. The division focuses on the sale, marketing and distribution of a wide range of medical aids and medical and nursing consumables.